Tim J. Wigle

5.6k citations

37 papers · 2.0k indexed · 1 hit paper · h-index 22

Molecular Biology top 5%
- Epigenetics and DNA Methylation 21
- Cancer-related gene regulation 18
- RNA modifications and cancer 10
- Histone Deacetylase Inhibitors Research 5
- Genomics and Chromatin Dynamics 5
Molecular Medicine top 5%
- Antibiotic Resistance in Bacteria 4
Oncology
- PARP inhibition in cancer therapy 5
Pathology and Forensic Medicine top 10%
Cancer Research
Electrical and Electronic Engineering
- Integrated Circuits and Semiconductor Failure Analysis 4

Co-authors: Robert A. Copeland Kevin W. Kuntz Mikel P. Moyer Margaret Porter Scott Sarah K. Knutson Heike Keilhack Victoria M. Richon Richard Chesworth
Cited by: Molecular Biology Molecular Medicine Oncology
Journals: SLAS DISCOVERY (4 papers)Cancer Research (3 papers)Journal of Medicinal Chemistry (3 papers)
Partner nations: United States Canada Germany

In The Last Decade

Tim J. Wigle

35 papers receiving 1.8k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Tim J. Wigle

Since Specialization

Citations

This map shows the geographic impact of Tim J. Wigle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim J. Wigle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim J. Wigle more than expected).

Fields of papers citing papers by Tim J. Wigle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim J. Wigle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim J. Wigle. The network helps show where Tim J. Wigle may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Tim J. Wigle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tim J. Wigle Line = papers co-authored together Tim J. Wigle links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	In Vitro and Cellular Probes to Study PARP Enzyme Target Engagement Cell chemical biology ·Tim J. Wigle,Michael Sierra-Arévalo,Laurie B. Schenkel,Yue Ren,浅沼良子,Sa Zhang,Kerren K. Swinger,Rosen Allyson,Christina R. Majer,Alvin Lu,Mario Niepel,Nicholas R. Perl,Melissa M. Vasbinder,Heike Keilhack,Kevin W. Kuntz	2020	17
2	Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation Biochemical Pharmacology ·Alvin Lu,Ryan Abo,Yue Ren,Bin Gui,Jan-Rung Mo,Michael Sierra-Arévalo,Tim J. Wigle,Heike Keilhack,Mario Niepel	2019	39
3	Forced Self-Modification Assays as a Strategy to Screen MonoPARP Enzymes SLAS DISCOVERY ·Tim J. Wigle,浅沼良子,Christina R. Majer,Kerren K. Swinger,Kadir Kadir,Laurie B. Schenkel,Melissa M. Vasbinder,Alexander Ilinsky,Nogueira,Okonkwo Christian Arinze,Dennis Wegener,Paul Chang,Kevin W. Kuntz	2019	17
4	A High-Throughput Mass Spectrometry Assay Coupled with Redox Activity Testing Reduces Artifacts and False Positives in Lysine Demethylase Screening SLAS DISCOVERY ·Tim J. Wigle,Kerren K. Swinger,John E. Campbell,Michael D. Scholle,John Sherrill,F Sauter,P. Ann Boriack‐Sjodin,Kevin W. Kuntz,Richard Chesworth,Mikel P. Moyer,Margaret Porter Scott,Robert A. Copeland	2015	31
5	Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound ACS Medicinal Chemistry Letters ·Lorna H. Mitchell,Allison E. Drew,Scott Ribich,Nathalie Rioux,Kerren K. Swinger,Suzanne L. Jacques,Trupti Lingaraj,P. Ann Boriack‐Sjodin,Nigel J. Waters,Tim J. Wigle,Oscar Moradei,Lei Jin,Thomas V. Riera,Julia Kuhrau,Mikel P. Moyer,J. Joshua Smith,Richard Chesworth,Robert A. Copeland	2015	95
6	Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas PLoS ONE ·Sarah K. Knutson,Natalie M. Warholic,L. Danielle Johnston,Christine R. Klaus,Tim J. Wigle,Yuyun Wahyuningrum,Bruce A. Littlefield,Julia Kuhrau,J. Joshua Smith,Mikel P. Moyer,Robert A. Copeland,Roy M. Pollock,Kevin W. Kuntz,Alejandra Raimondi,Heike Keilhack	2014	55
7	Drugging the human methylome: an emerging modality for reversible control of aberrant gene transcription Current Opinion in Chemical Biology ·Tim J. Wigle,Robert A. Copeland	2013	17
8	A687V EZH2 is a gain‐of‐function mutation found in lymphoma patients FEBS Letters ·Christina R. Majer,Lei Jin,Margaret Porter Scott,Sarah K. Knutson,Kevin W. Kuntz,Heike Keilhack,J. Joshua Smith,Mikel P. Moyer,Victoria M. Richon,Robert A. Copeland,Tim J. Wigle	2012	116
9	Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L Chemical Biology & Drug Design ·Aravind Basavapathruni,Lei Jin,Scott R. Daigle,Christina R. Majer,正樹北薗,Tim J. Wigle,Kevin W. Kuntz,Richard Chesworth,Roy M. Pollock,Margaret Porter Scott,Mikel P. Moyer,Victoria M. Richon,Robert A. Copeland,Edward J. Olhava	2012	114
10	Promoting Illiteracy in Epigenetics: An Emerging Therapeutic Strategy PubMed ·Tim J. Wigle	2011	5
11	The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states FEBS Letters ·Tim J. Wigle,Sarah K. Knutson,Lei Jin,Kevin W. Kuntz,Roy M. Pollock,Victoria M. Richon,Robert A. Copeland,Margaret Porter Scott	2011	62
12	Small-Molecule Ligands of Methyl-Lysine Binding Proteins Journal of Medicinal Chemistry ·J. Martin Herold,Tim J. Wigle,Jacqueline L. Norris,Robert Lam,Victoria Korboukh,Cen Gao,Zhouxia Jia,Dmitri Kireev,Guillermo Senisterra,Masoud Vedadi,Ashutosh Tripathy,Peter J. Brown,C.H. Arrowsmith,Jian Jin,William P. Janzen,Stephen V. Frye	2011	92
13	Accessing Protein Methyltransferase and Demethylase Enzymology Using Microfluidic Capillary Electrophoresis Chemistry & Biology ·Tim J. Wigle,Maritza Llerena,Jacqueline L. Norris,Jian Jin,Peter J. Brown,Stephen V. Frye,William P. Janzen	2010	36
14	Epigenetics: tools and technologies Drug Discovery Today Technologies ·William P. Janzen,Tim J. Wigle,Jian Jin,Stephen V. Frye	2010	29
15	Novel Inhibitors of E. coli RecA ATPase Activity PubMed ·Jonathan Z. Sexton,Tim J. Wigle,Qingping He,Mark Hughes,M West Greenlee,Scott F. Singleton,Alfred L. Williams,Li-An Yeh	2010	56
16	Inhibitors of RecA Activity Discovered by High-Throughput Screening: Cell-Permeable Small Molecules Attenuate the SOS Response in Escherichia coli SLAS DISCOVERY ·Tim J. Wigle,Jonathan Z. Sexton,Anna V. Gromova,Mallinath B. Hadimani,Mark Hughes,M West Greenlee,Li-An Yeh,Scott F. Singleton	2009	48
17	Screening for Inhibitors of Low-Affinity Epigenetic Peptide-Protein Interactions: An AlphaScreen™-Based Assay for Antagonists of Methyl-Lysine Binding Proteins SLAS DISCOVERY ·Tim J. Wigle,J. Martin Herold,Guillermo Senisterra,Masoud Vedadi,Dmitri Kireev,C.H. Arrowsmith,Stephen V. Frye,William P. Janzen	2009	65
18	A complementary pair of rapid molecular screening assays for RecA activities Analytical Biochemistry ·Andrew M. Lee,Tim J. Wigle,Scott F. Singleton	2007	16
19	Directed molecular screening for RecA ATPase inhibitors Bioorganic & Medicinal Chemistry Letters ·Tim J. Wigle,Scott F. Singleton	2007	61
20	Conformationally Selective Binding of Nucleotide Analogues to Escherichia coli RecA: A Ligand-Based Analysis of the RecA ATP Binding Site Biochemistry ·Tim J. Wigle,Andrew M. Lee,Scott F. Singleton	2006	22

About Tim J. Wigle

Tim J. Wigle is a scholar working on Molecular Medicine, Molecular Biology, Physiology, Oncology and Genetics, having authored 37 papers that have together received 2.0k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (21 papers), Cancer-related gene regulation (18 papers), RNA modifications and cancer (10 papers), Histone Deacetylase Inhibitors Research (5 papers), PARP inhibition in cancer therapy (5 papers), Genomics and Chromatin Dynamics (5 papers), Antibiotic Resistance in Bacteria (4 papers) and Integrated Circuits and Semiconductor Failure Analysis (4 papers). The work is most often cited by research in Molecular Biology (1.7k citations), Molecular Medicine (103 citations), Oncology (224 citations), Pathology and Forensic Medicine (138 citations) and Cancer Research (103 citations). Tim J. Wigle has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Robert A. Copeland, Kevin W. Kuntz, Mikel P. Moyer, Margaret Porter Scott, Sarah K. Knutson, Heike Keilhack, Victoria M. Richon, Richard Chesworth, Roy M. Pollock and Scott F. Singleton. Their work appears in journals such as SLAS DISCOVERY, Cancer Research, Journal of Medicinal Chemistry, ACS Medicinal Chemistry Letters and FEBS Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact